GAIN THERAPEUTICS INC (GANX)

Company Profile

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 28 full-time employees. The company went IPO on 2021-03-18. The firm is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. Its drug discovery platform, Site-Directed Enzyme Enhancement Therapy (SEE-Tx), to discover novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.

Company Info

GAIN THERAPEUTICS INC

4800 Hampden Lane, Suite 200

Bethesda MARYLAND 20814

P: 13015001556.0

CEO: Eric Richman

Employees: 28

Website: https://www.gaintherapeutics.com/